Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general, and administrative

Research and development

Amortization of acquired intangibles

Restructuring - operating expenses

Acquisition related expenses

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

ResMed

ResMed, Inc. engages in providing digital health and cloud-connected medical devices. Its digital health technologies and cloud-connected medical devices transform care for people with sleep apnea, chronic obstructive pulmonary disease, or COPD, and other chronic diseases. The firm operates through the Sleep and Respiratory Care and Software as a Service segments. The Sleep and Respiratory Care segment engages in the sleep and respiratory disorders sector of the medical device industry. The Software as a Service segment provides business management software as a service to out-of-hospital health providers. The company was founded by Peter C. Farrell in June 1989 and is headquartered in San Diego, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Earnings data Q1 2025

Earnings data Q2 2025

ResMed reports robust Q1 performance, eyes margin expansion and partnerships

ResMed's Q1 2023 performance reflects strong revenue growth and a focus on meeting global demand for connected CPAP and APAP devices. The company faces challenges in maintaining gross margins and managing operating expenses but sees opportunities in expanding margins and engaging with new patient segments.

ResMed reports robust Q2 earnings, eyes growth through innovation

ResMed's Q2 2023 earnings call highlighted strong sales growth, increased revenue, and a focus on innovation.
Challenges in supply chain constraints and operating expenses were noted, alongside opportunities in growth drivers.
The company aims to improve lives through respiratory care solutions and digital health innovations by 2025.
ResMed's performance reflects post-COVID awareness of respiratory health importance and customer acceptance of new devices.

ResMed reports robust Q3 performance, eyes global growth opportunities

ResMed's Q3 earnings call highlighted strong financial performance, growth in device revenue and mask sales, and a focus on sustaining profitable growth. The company aims to address challenges in gross margin decline by leveraging opportunities for expansion and reinvestment in growth.

ResMed reports strong Q4 earnings, eyes international growth opportunities

ResMed's Q4 2023 showcased robust financial performance with revenue and earnings growth.
The company's focus on patient care, innovation, and international expansion presents promising opportunities.
Challenges include managing operating expenses, gross margin decline, and pricing dynamics.
Strategic initiatives to improve gross margins and drive revenue growth position ResMed well for the future.

ResMed reports 16% revenue growth in Q1 2024 earnings call

ResMed's Q1 2024 performance showcased revenue growth driven by strong device and mask sales globally.
Despite challenges like margin decline and increased expenses, the company's strategic focus on core business and innovation remains strong.
Opportunities lie in expanding alternative therapies, sustaining growth in devices and masks, and optimizing the SaaS business.
Overall, ResMed is positioned for accelerated profitable growth, prioritizing cost optimization and key initiatives for future success.

ResMed reports strong Q2 earnings, eyes global healthcare expansion

ResMed's Q2 2024 earnings call showcased robust financial performance, strategic priorities in healthcare innovation, and a focus on delivering value through patient care. Despite challenges, the company remains optimistic about growth potential and stakeholder engagement in its mission.

ResMed reports strong Q3 results, eyes global expansion and innovation

ResMed's Q3 earnings call showcased solid financial performance, operational improvements, and a strategic focus on market expansion. With a strong emphasis on innovation and cost discipline, the company is poised for continued growth despite challenges.

ResMed reports robust Q4 growth, eyes digital health opportunities

ResMed's Q4 performance was strong, driven by robust growth and financial stability.
While facing challenges like medication impact and market expansion, opportunities in digital health and partnerships exist.
The company's focus on patient awareness and demand generation remains key to future growth.
Overall, ResMed's strategic initiatives position it well for continued success and innovation.

ResMed excels in Q1 with strong revenue growth and innovation

ResMed's Q1 performance reflects strong revenue growth, product success, and strategic investments.
The company's strengths lie in innovation, supply chain optimization, and proactive growth strategies.
Challenges include competitive pressures, addressing new patient demand, and balancing acquisitions with operational efficiency.
Opportunities abound in digital health, customer partnerships, and expanding patient care pathways.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Brown & Brown

Markel

With the markets in flux, bargain hunters may have some prime opportunities to load up on quality names this week. Brown & Brown, Markel, and ResMed are three top-notch growth stocks worth considering in any market.

3 Incredible Growth Stocks to Buy Right Now

Investors are optimistic about ResMed's (RMD) Increased demand for its digital health solution.

Reasons Why You Should Retain ResMed (RMD) Stock For Now

SAN DIEGO, March 15, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will join a fireside chat at the 2023 KeyBanc Life Sciences & MedTech Investor Forum on Tuesday, March 21, 2023, beginning at approximately 3:45 p.m. (Eastern Daylight Time) via webcast.

ResMed Announces Participation in the 2023 KeyBanc Life Sciences & MedTech Investor Forum

SAN DIEGO, March 13, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) announced today the results from its 2023 Global Sleep Survey in conjunction with National Sleep Awareness Week (March 12-18) and World Sleep Day (March 17) to raise awareness for the importance of sleep as a key component of physical and mental health.

ResMed's Annual Global Sleep Survey Finds 8 in 10 Adults Experience Signs of Disruption Related to Their Quality of Sleep

National Vision Hlds

EYE vs. RMD: Which Stock Is the Better Value Option?

EYE vs. RMD: Which Stock Should Value Investors Buy Now?

SAN DIEGO, March 07, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Rob Douglas, president and chief operating officer, will present at the Oppenheimer 33rd Annual Healthcare Conference on Monday, March 13, 2023, beginning at approximately 11:20 a.m. (Eastern Daylight Time) via webcast.

ResMed Announces Participation in the Oppenheimer 33rd Annual Healthcare Conference

ResMed (RMD) continues to see robust demand for its market-leading mask portfolio despite being faced with challenges related to lower new patient setups from a competitor recall.

ResMed's (RMD) Mask Sales Drive Growth, Margin Issue Lingers

ResMed continues to be a leading company in the industry, with multiple growth drivers ahead of its 2025 goals. But the outlook for ResMed doesn't look good, with YoY figures slowing and dividend payments possibly being interrupted.

ResMed: Bulls Can Rest For Now, For Its Declining Cash Flow Performance

EssilorLuxottica SA

ESLOY vs. RMD: Which Stock Is the Better Value Option?

ResMed's (RMD) mask sales growth was strong across the globe, reflecting a post-COVID pandemic awareness about the importance and need for respiratory hygiene and respiratory health.

ResMed's (RMD) Q2 Earnings Beat Estimates, Margins Falls

ResMed Inc. (NYSE:RMD ) Q2 2023 Earnings Conference Call January 26, 2023 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO and Chairman Brett Sandercock - CFO Rob Douglas - President and COO Conference Call Participants Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Matthew Mishan - KeyBanc Capital Markets Steve Wheen - Jarden David Bailey - Macquarie Mike Matson - Needham & Company Craig Wong-Pan - RBC Sean Laaman - Morgan Stanley Margaret Kaczor - William Blair Matt Taylor - Jefferies Michael Polark - Wolfe Research Saul Hadassin - Barrenjoey Capital David Low - JPMorgan Dan Hurren - MST Marquee Lyanne Harrison - Bank of America Operator Hello and welcome to the ResMed Second Quarter Fiscal Year 2023 Earnings Call. At this time, all participants are in a listen-only mode.

ResMed Inc. (RMD) Q2 2023 Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 3.75% and 3.64%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q2 Earnings and Revenues Surpass Estimates

SAN DIEGO, Jan. 26, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced ResMed's board of directors has appointed chief executive officer Michael (“Mick”) Farrell as chair of the board, effective January 25, 2023. Mr. Farrell succeeds current chair Peter Farrell who will become chair emeritus and will remain an active board member.

ResMed Appoints Michael Farrell as Chair of its Board of Directors Peter Farrell to Become Chair Emeritus

Note: A webcast of ResMed's conference call will be available at 4:30 p.m. ET today at  http://investor.resmed.com

ResMed Inc. Announces Results for the Second Quarter of Fiscal Year 2023

SAN DIEGO, Jan. 12, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the second quarter of fiscal year 2023 on Thursday, January 26, 2023, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast.

ResMed to Report Second Quarter Fiscal 2023 Earnings on January 26, 2023

SAN DIEGO, Jan. 02, 2023 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced Mick Farrell, chief executive officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023, beginning at approximately 1:30 p.m. (Pacific Standard Time) at the Westin St. Francis in San Francisco, CA.

ResMed Announces Participation in the 41st Annual J.P. Morgan Healthcare Conference

-  Acquisition expands ResMed's SaaS business to Germany, first non-U.S. market

ResMed Completes Acquisition of MEDIFOX DAN, a German Leader in Out-of-Hospital Care Management Software Solutions

SINGAPORE, Nov. 17, 2022 (GLOBE NEWSWIRE) -- ResMed this week celebrated the grand opening of its new Advanced Manufacturing Centre in Tuas, Singapore.

ResMed Opens Manufacturing Centre in Singapore, Expanding Manufacturing Footprint to Support Growth, Development, and Production of Digital Health Solutions

ResMed is a potential opportunity for retail value investors to profit from this low-risk market leader, but there are several issues that worry us - the share price is high. The company revenue consistently grows in a niche of the healthcare device industry that will annually increase about 6% to almost $6B in revenue.

ResMed Inc. Lets Investors Breath Easy

U.S. medical device equities have not been a source of safety or growth in 2022. ResMed's diversified businesses help its earnings growth outlook through 2025. The PEG ratio looks attractive.

ResMed: Strong Earnings Growth Supports The High Valuation, Unclear Technical Trends

ResMed (RMD) continues to increase its access to semiconductor communications chips.

ResMed (RMD) Q1 Earnings In Line, Operating Margin Falls

ResMed Inc. (NYSE:RMD ) Q1 2023 Earnings Conference Call October 27, 2022 4:30 PM ET Company Participants Amy Wakeham - VP, IR & Corporate Communications Mick Farrell - CEO & Director Brett Sandercock - CFO Rob Douglas - President, COO and Interim President, Sleep & Respiratory Care David Pendarvis - Chief Administrative Officer and Global General Counsel Conference Call Participants Steve Wheen - Jarden Matt Mishan - KeyBanc Gretel Janu - Credit Suisse Saul Hadassin - Barrenjoey Capital Dan Hurren - MST Marquee Mike Matson - Needham David Bailey - Macquarie Lyanne Harrison - Bank of America Craig Wong-Pan - RBC Chris Cooper - Goldman Sachs Suraj Kalia - Oppenheimer Margaret Kaczor - William Blair Mathieu Chevrier - Citi Steve Wheen - Jarden Limited Operator Hello, and welcome to the ResMed First Quarter Fiscal 2023 Earnings Call. At this time, all participants are in a listen-only mode.

ResMed Inc. (RMD) Q1 2023 Results - Earnings Call Transcript

ResMed (RMD) delivered earnings and revenue surprises of 0% and 0.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

ResMed (RMD) Q1 Earnings Match Estimates

ResMed Inc. Announces Results for the First Quarter of Fiscal Year 2023

SAN DIEGO, Oct. 13, 2022 (GLOBE NEWSWIRE) -- ResMed (NYSE: RMD, ASX: RMD) today announced it plans to release financial and operational results for the first quarter of fiscal year 2023 on Thursday, October 27, 2022, after the New York Stock Exchange closes. Following the release, ResMed management will host a webcast to discuss these results. Other forward-looking and material information may also be discussed during this webcast.

News for ResMed Stock (RMD)